Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Christopher Vargas headshot

Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors

by Christopher Vargas

Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.

J&J Settles Ahead of Multi-District Opioid Trial, Stock Up

by Zacks Equity Research

J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.

Mallinckrodt Up on Settlement Agreement With Ohio Counties

by Zacks Equity Research

Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.

Mallinckrodt's StrataGraft Tissue Phase III Data Positive

by Zacks Equity Research

Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.

Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up

by Zacks Equity Research

Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

by Zacks Equity Research

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties

by Zacks Equity Research

Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.

Endo International Files BLA for Label Expansion of Xiaflex

by Zacks Equity Research

Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.

Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation

by Zacks Equity Research

Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.

Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

by Zacks Equity Research

Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.

Endo (ENDP) Up 5.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan Settles Ahead of Multi-District Opioid Litigation

by Zacks Equity Research

Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.

Indrajit Bandyopadhyay headshot

Will Opioid Litigation Take its Toll on Pharma Companies?

by Indrajit Bandyopadhyay

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case

by Zacks Equity Research

A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.

Case-Shiller Index Nudges Up

by Zacks Equity Research

Case-Shiller Index Nudges Up

Mark Vickery headshot

J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read

by Mark Vickery

Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.

J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week

by Zacks Equity Research

J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.

Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits

by Zacks Equity Research

Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.

Endo Up on Settlement of a Few Cases Related to Opioid Drugs

by Zacks Equity Research

Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.

Are Options Traders Betting on a Big Move in Endo (ENDP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

Is Endo International (ENDP) A Great Pick for Value Investors?

by Zacks Equity Research

Is Endo International Holdings (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2

by Zacks Equity Research

BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.

Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

by Zacks Equity Research

Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

Endo International (ENDP) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.